Navigation Links
Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases

advance in the understanding of autoimmune diseases that collectively affect an estimated 15 million to 25 million Americans. The more we understand about these diseases, including the genes that predispose to them and the environmental factors that trigger them, the closer we come to better treatments and even preventive measures, he says.

Additional support for this research was provided by the National Institute of Allergy and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, the U.K. Vitiligo Society and the National Vitiligo Foundation.

The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the Department of Health and Human Services National Institutes of Health, is to support research into the causes, treatment and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases. For more information about NIAMS, call the information clearinghouse at (301) 495-4484 or (877) 22-NIAMS (free call) or visit the NIAMS Web site at http://www.niams.nih.gov.

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

CONTACT:
Ray Fleming
301-496-8190


'"/>




Page: 1 2 3

Related medicine technology :

1. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
2. Schepens Scientists Identify Key to Integrating Transplanted Nerve Cells Into Injured Tissue
3. Karmanos Physician-Scientists Examine Racial Disparities in Patients with Gynecologic Cancer
4. The Sturdier Sex?: Study by Pittsburgh Scientists Finds Female Stem Cells Work Better
5. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
6. Scottish Scientists Test ‘Secret Weapon’ Against Tumours
7. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
8. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
9. New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
10. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
11. Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex
Post Your Comments:
(Date:5/16/2008)... Highlights Include:, -- Results demonstrating th...linically meaningful extension of progression-free...mab to attack both the inside and,outside of the H...ade, -- Data demonstrating activity of TYKERB alo...ple lines of trastuzumab and chemotherapy, LONDON...
(Date:5/16/2008)... MicroRNAs as Potential Biomarkers -- for Lung Ca... in Patients With Cancer of Unknown Primary ...tively Identify Cancer Types With High Sensitivity...sis and Treatment of Cancer Results of microRNA S... Accuracy Exceeding 90% and Specificity of...
(Date:5/16/2008)...Single Molecule with Dual Mechanism May Offer Nove...ure Management, NEW ORLEANS, May 16 /PRNewswire-F...ator in the discovery and development of novel sma...33540, its first-in-class,Dual Acting Receptor Ant...lood pressure reductions in a Phase 2a study in pa...
(Date:5/15/2008)...Trial Results Confirm Efficacy for Population Most...E, Calif., May 16 /-,Bayer ...uticals, Inc.,(Nasdaq: ONXX ) today announced tha...roved overall survival by 47.3 percent (HR=0.68;,p...on with advanced,hepatocellular carcinoma (HCC), o...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 2Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 3Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 4Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 5Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study 6PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements 16784 1PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements 16784 2CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday April 25 2008 16781 1CV Therapeutics to Announce 2008 First Quarter Financial Results on Friday April 25 2008 16781 2TOFUTTI Announces 2007 Results 16776 1TOFUTTI Announces 2007 Results 16776 2TOFUTTI Announces 2007 Results 16776 3TOFUTTI Announces 2007 Results 16776 4TOFUTTI Announces 2007 Results 16776 5Testosterone Spray Improves Sexual Satisfaction in Women 16771 1Testosterone Spray Improves Sexual Satisfaction in Women 16771 2
... June 4, 2007 – Data presented,today at this...y,(ASCO) meeting in Chicago show that a novel comb...-fluorouracil (5-FU) therapy UFT,(tegafur–ur...response rate in the first-line treatment of metas...dy (Study of CPT-11 with Oxaliplatin combined,with...
...ing a clinically relevant model of,normal human sk...,of abrogating the cytotoxic effect of erlotinib *...m) agent was generally well,tolerated in metastati...similar to conventional vincristine , SOUTH SAN FR...Hana Biosciences (Nasdaq:HNAB), a biopharmaceutica...
Other Medicine Technology:Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 2Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 3Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 2Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 3Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 4Hana Biosciences Presents Data On Two Programs At the American,Society of Clinical Oncology Annual Meeting 5
(Date:5/16/2008)... that Primary care medicine is in a precipitous de...merican College of Physicians (ACP), today joined...sumers to issue a call for comprehensive reforms t...nd other primary care physicians. , During a pa...ne in the U.S., Dr. Dale and other panelists spoke...
(Date:5/16/2008)...ervices for Frail Seniors and People With,Disabili...ire/ -- Thousands of,homecare workers across the s...proposed cuts to hours of service, wages and benef...ulnerable workers and the,people they serve deeper...rvices for seniors and people with disabilities fr...
(Date:5/16/2008)...alth Institute with 10,000 Sensual O Condom Packs ...Mansion Fundraiser, LOS ANGELES, May 16 /PRNewswi... B artist J Kwon known best for his hit song "Ever...ng the Urban Health Institute (UHI) with,10,000 Se... The donation is,being made to promote the launch ...
(Date:5/16/2008)... who would benefit most from chemo after surgery, ... News) -- A panel of 15 genes may help determine w... cancer will experience a recurrence and, therefor... shows. , By extension, the same genetic signa...ve forms of the cancer who would be able to forego...
Breaking Medicine News(10 mins):Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3
...lowing detection of Alzheimer's disease in a forme...vey calls for further testing of people // who res...oning in 1988. The suggestion has been made in a J... Psychiatry. The death of resident Carole Cross, ...
...ording to an Irish researcher, frequent hiccups to...ng may be an indication of esophageal cancer. // ...e James Connolly Memorial Hospital in Dublin, told...geons in Ireland that 27 percent of patients with ...
...nsplant experts in Britain have accused China of r... them without prior consent of the prisoners and t...ich highlights that organs from executed prisoners...tation purposes in an illegal way, according to re...
...ional Health Service (NHS) which initially funded ...ding the laser treatment to remove the tattoos. //...eds the ?2,500 laser treatment because her tattoos...evless dresses in the summer. Middleton and Heywo...
Other Medicine News:Health News:Call For Testing Of Poisoned Town: Risk Of Alzheimer's Disease 2Health News:Executed Prisoner Organs For Sale In China: BTS Concerned 2
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm.
Medicine Products: